FibroGen, Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 18,900 shares of FibroGen stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $54.83, for a total transaction of $1,036,287.00. Following the completion of the transaction, the chief executive officer now directly owns 3,176,861 shares in the company, valued at approximately $174,187,288.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of FibroGen, Inc (NASDAQ:FGEN) traded down 0.45% during mid-day trading on Wednesday, hitting $55.05. 371,377 shares of the stock were exchanged. The stock’s market capitalization is $3.92 billion. FibroGen, Inc has a 12-month low of $15.60 and a 12-month high of $60.15. The stock’s 50 day moving average price is $52.02 and its 200-day moving average price is $36.39.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The company had revenue of $29.00 million for the quarter, compared to analyst estimates of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. On average, equities research analysts expect that FibroGen, Inc will post ($1.81) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/10/18/fibrogen-inc-fgen-ceo-sells-1036287-00-in-stock.html.

Several hedge funds have recently made changes to their positions in FGEN. Ameritas Investment Partners Inc. acquired a new stake in shares of FibroGen during the 1st quarter worth approximately $111,000. Quantbot Technologies LP acquired a new stake in FibroGen in the 2nd quarter valued at $128,000. SG Americas Securities LLC grew its position in FibroGen by 6.5% in the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 412 shares during the period. Amalgamated Bank acquired a new stake in FibroGen in the 2nd quarter valued at $237,000. Finally, BNP Paribas Arbitrage SA grew its position in FibroGen by 589.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,401 shares of the biopharmaceutical company’s stock valued at $239,000 after purchasing an additional 6,327 shares during the period. 47.49% of the stock is owned by institutional investors.

A number of brokerages have weighed in on FGEN. Leerink Swann reaffirmed an “outperform” rating and issued a $82.00 price target (up previously from $52.00) on shares of FibroGen in a research note on Tuesday, August 8th. William Blair reaffirmed an “outperform” rating on shares of FibroGen in a research note on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $75.00 price target on shares of FibroGen in a research note on Tuesday, August 8th. Citigroup Inc. lifted their price target on shares of FibroGen from $48.00 to $65.00 and gave the company a “top pick” rating in a research note on Tuesday, August 8th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $38.00 price target (up previously from $32.00) on shares of FibroGen in a research note on Thursday, June 22nd. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. FibroGen currently has a consensus rating of “Buy” and a consensus target price of $65.67.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.